0000899243-19-029433.txt : 20191217
0000899243-19-029433.hdr.sgml : 20191217
20191217164223
ACCESSION NUMBER: 0000899243-19-029433
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191217
FILED AS OF DATE: 20191217
DATE AS OF CHANGE: 20191217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Faga Daniel
CENTRAL INDEX KEY: 0001673528
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36819
FILM NUMBER: 191290250
MAIL ADDRESS:
STREET 1: 3737 MARKET STREET
STREET 2: SUITE 1300
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Spark Therapeutics, Inc.
CENTRAL INDEX KEY: 0001609351
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 462654405
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3737 MARKET STREET
STREET 2: SUITE 1300
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
BUSINESS PHONE: 888-772-7560
MAIL ADDRESS:
STREET 1: 3737 MARKET STREET
STREET 2: SUITE 1300
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-12-17
1
0001609351
Spark Therapeutics, Inc.
ONCE
0001673528
Faga Daniel
3737 MARKET STREET
SUITE 1300
PHILADELPHIA
PA
19104
0
1
0
0
Chief Business Officer
Common Stock
2019-12-17
4
U
0
38828
114.50
D
0
D
Stock Option (Right to Buy)
42.73
2019-12-17
4
D
0
35000
0.00
D
2029-01-15
Common Stock
35000
0
D
Stock Option (Right to Buy)
50.55
2019-12-17
4
D
0
26250
0.00
D
2028-01-17
Common Stock
26250
0
D
Stock Option (Right to Buy)
56.17
2019-12-17
4
D
0
14000
0.00
D
2027-01-17
Common Stock
14000
0
D
Stock Option (Right to Buy)
37.62
2019-12-17
4
D
0
50000
0.00
D
2026-05-01
Common Stock
50000
0
D
Restricted Stock Units
0.00
2019-12-17
4
D
0
21500
0.00
D
Common Stock
21500
0
D
Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).
/s/ Joseph W. La Barge, Attorney-in-Fact
2019-12-17